



an Open Access Journal by MDPI

STAT3 in Carcinogenesis: Update from 1993 to Present

Guest Editors:

Dr. Donatella Romaniello

Department of Experimental,
Diagnostic and Specialty
Medicine (DIMES), University of
Bologna, 40138 Bologna, Italy

Dr. Ilaria Marrocco

Department of Life Sciences and
Public Health, Università
Cattolica del Sacro Cuore, Rome,
Italy

Dr. Margherita Eufemi

Department of Biochemical
Sciences, Università degli Studi di
Roma La Sapienza, Rome, Italy

Deadline for manuscript
submissions:

closed (30 November 2023)

Message from the Guest Editors

Dear Colleagues,

Signal Transducer and Activator of Transcription 3 (STAT3) is a 30-year-old protein. As a pro-inflammatory transcription factor, signal transducer, and transcription activator, it was identified in 1994. Its activation is crucial in various *diseases as chronic inflammation, cardiovascular and metabolic disorders*, and cancer. In fact, a lot of scientific publications assessed the involvement of STAT3, through both its canonical and non-canonical pathways. Its multifaceted activities are mainly ensured by post-translational modifications such as phosphorylation, acetylation, glutathionylation, etc.

This Special Issue aims to review all the scientific advances on the STAT3 protein achieved in the past 30 years focusing on current and future research on the role of the STAT3 protein, its potential inhibitors or modulators in both carcinogenesis and chemoresistance phenomenon. We hope that researchers in the field contribute with research articles, review articles, innovative hypotheses, or commentaries on STAT3's activities and regulations.

Dr. Donatella Romaniello

Dr. Ilaria Marrocco

Dr. Margherita Eufemi

Guest Editors



mdpi.com/si/175942

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI